13212 results
-
List item
Human medicine European public assessment report (EPAR): Docetaxel Zentiva (previously Docetaxel Winthrop)
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 20/04/2007, Revision: 30, Authorised, Last updated: 20/12/2019Docetaxel Zentiva (previously Docetaxel Winthrop) Head and Neck … Authorised docetaxel Overview Docetaxel Zentiva is a cancer medicine … of cancer: breast cancer. Docetaxel Zentiva can be used on its … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Teva
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 26/01/2010,
, Revision: 18, Authorised, Last updated: 23/11/2020
Docetaxel Teva Head and Neck Neoplasms Carcinoma … Authorised docetaxel Overview Docetaxel Teva is a cancer medicine … of cancer: breast cancer. Docetaxel Teva can be used on its own … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Kabi
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 22/05/2012,, Revision: 14, Authorised, Last updated: 28/10/2020
Docetaxel Kabi Head and Neck Neoplasms Carcinoma … Authorised docetaxel Overview Docetaxel Kabi is a cancer medicine … of cancer: breast cancer. Docetaxel Kabi can be used on its own … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Accord
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 22/05/2012,, Revision: 14, Authorised, Last updated: 28/10/2020
Docetaxel Accord Head and Neck Neoplasms Carcinoma … Authorised docetaxel Overview Docetaxel Accord is a cancer medicine … of cancer: breast cancer. Docetaxel Accord can be used on its … -
List item
Withdrawn application: Docetaxel Zentiva (previously Docetaxel Winthrop)
docetaxel, date of withdrawal: 14/11/2008, Post-authorisation, Last updated: 17/11/2008Docetaxel Winthrop: Withdrawn applicati … acknowledged. London, 24 July 2008 Doc. Ref. EMEA/384759/2008 … AUTHORISATION for Taxotere/Docetaxel Winthrop International … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Mylan
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Breast Neoplasms
Date of authorisation: 31/01/2012,, Revision: 6, Withdrawn, Last updated: 12/03/2015
Docetaxel Mylan Head and Neck Neoplasms Carcinoma … Withdrawn docetaxel Overview The marketing authorisation … marketing authorisation for Docetaxel Mylan has lapsed becasue … -
List item
Human medicine European public assessment report (EPAR): Docefrez
docetaxel, Stomach Neoplasms, Adenoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms
Date of authorisation: 10/05/2010,, Revision: 1, Withdrawn, Last updated: 14/06/2012
Docefrez Stomach Neoplasms Adenoma Breast … Withdrawn docetaxel Overview The marketing authorisation … marketing authorisation for Docefrez has been withdrawn at the … -
List item
Withdrawn application: Docetaxel Mylan
docetaxel, date of withdrawal: 08/03/2010, Initial authorisation, Last updated: 26/03/2010Docetaxel Mylan: Withdrawn application … authorisation application for Docetaxel Mylan docetaxel) On 8 March 2010, Mylan … marketing authorisation for Docetaxel Mylan intended to be used … -
List item
Human medicine European public assessment report (EPAR): Docetaxel Teva Pharma
docetaxel, Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Prostatic Neoplasms
Date of authorisation: 21/01/2011,, Revision: 6, Withdrawn, Last updated: 21/01/2014
Docetaxel Teva Pharma Carcinoma, Non-Small-Cell … Withdrawn docetaxel Overview The marketing authorisation … marketing authorisation for Docetaxel Teva Pharma has lapsed because … -
List item
Withdrawn application: Docetaxel SUN
docetaxel, date of withdrawal: 06/06/2016, Initial authorisation, Last updated: 29/09/2016Docetaxel SUN: Withdrawn application … authorisation application for Docetaxel Sun docetaxel) On 6 June 2016, Sun … marketing authorisation for Docetaxel Sun, for the treatment of … -
List item
Human medicine European public assessment report (EPAR): Taxespira (previously Docetaxel Hospira UK Limited )
docetaxel trihydrate, Stomach Neoplasms, Prostatic Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 28/08/2015,, Revision: 8, Withdrawn, Last updated: 15/10/2019
Taxespira (previously Docetaxel Hospira UK Limited ) Stomach … Withdrawn docetaxel Overview The marketing authorisation … authorisation holder. Summary documents Taxespira (previously Docetaxel Hospira UK Limited) : EPAR … -
List item
Human medicine European public assessment report (EPAR): Taxotere
docetaxel, Head and Neck Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Prostatic Neoplasms, Stomach Neoplasms, Breast Neoplasms
Date of authorisation: 27/11/1995, Revision: 48, Authorised, Last updated: 03/12/2020Authorised docetaxel Overview Taxotere is a cancer … contains the active substance docetaxel. How is Taxotere used? Taxotere … under the supervision of a doctor who is qualified in the use … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Taxotere, docetaxel
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Oncology
PIP number: Docetaxel, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate and solvent for solution for infusion
Decision date: 16/05/2008, Last updated: 04/06/2008, Compliance check: XDocetaxel Oncology … Key facts Taxotere docetaxel OncologyP/22/2008 Docetaxel Concentrate and solvent for … Paediatric Investigation Plan for Docetaxel, Taxotere (EMEA-000029-PIP01-07 … -
List item
Withdrawn application: Taxotere
docetaxel, date of withdrawal: 14/11/2008, Post-authorisation, Last updated: 17/11/2008acknowledged. London, 24 July 2008 Doc. Ref. EMEA/384759/2008 … AUTHORISATION for Taxotere/Docetaxel Winthrop International … non-proprietary name (INN): docetaxel On 24 July 2008, the Committee … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel/Acetylsalicylic acid Teva
clopidogrel, acetylsalicylic acid, Acute Coronary Syndrome, Myocardial Infarction
Date of authorisation: 01/09/2014, Revision: 1, Withdrawn, Last updated: 28/04/2017Clopidogrel/Acetylsalicylic acid Teva Acute Coronary … Withdrawn clopidogrelacetylsalicylic acid Overview The marketing … marketing authorisation for Clopidogrel/Acetylsalicylic acid Teva has been withdrawn … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Zentiva (previously Clopidogrel Winthrop)
clopidogrel, Stroke, Peripheral Vascular Diseases, Myocardial Infarction, Acute Coronary Syndrome
Date of authorisation: 15/07/2008, Revision: 27, Authorised, Last updated: 02/02/2021Clopidogrel Zentiva (previously Clopidogrel Winthrop) Stroke Peripheral … Authorised clopidogrel Overview This is a summary … assessment report (EPAR) for Clopidogrel Zentiva. It explains how … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Taw Pharma (previously Clopidogrel Apotex)
clopidogrel (as besilate), Peripheral Vascular Diseases, Stroke, Myocardial Infarction
Date of authorisation: 16/10/2009,, Revision: 20, Authorised, Last updated: 17/02/2021
Clopidogrel Taw Pharma (previously Clopidogrel Apotex) Peripheral Vascular … Authorised clopidogrel Overview This is a summary … assessment report (EPAR) for Clopidogrel Apotex. It explains how the … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)
clopidogrel, acetylsalicylic acid, Acute Coronary Syndrome, Myocardial Infarction
Date of authorisation: 14/03/2010, Revision: 22, Authorised, Last updated: 13/11/2019Clopidogrel/Acetylsalicylic acid Zentiva (previously … Authorised clopidogrelacetylsalicylic acid Overview This document is a summary of the European … Assessment Report (EPAR) for Clopidogrel/Acetylsalicylic acid Zentiva. It explains … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Teva Pharma (previously Clopidogrel HCS)
clopidogrel (as hydrochloride), Myocardial Infarction, Peripheral Vascular Diseases, Stroke
Date of authorisation: 21/09/2009,, Revision: 9, Withdrawn, Last updated: 24/10/2017
Clopidogrel Teva Pharma (previously Clopidogrel HCS) Myocardial Infarction Peripheral … Withdrawn clopidogrel Overview The marketing authorisation … marketing authorisation for Clopidogrel Teva Pharma has been withdrawn … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Acino
clopidogrel, Peripheral Vascular Diseases, Acute Coronary Syndrome, Myocardial Infarction, Stroke
Date of authorisation: 28/07/2009,, Revision: 6, Withdrawn, Last updated: 04/01/2018
Clopidogrel Acino Peripheral Vascular … Withdrawn clopidogrel Overview The marketing authorisation … marketing authorisation for Clopidogrel Acino has been withdrawn … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm
clopidogrel, Peripheral Vascular Diseases, Stroke, Myocardial Infarction
Date of authorisation: 23/09/2009,, Revision: 5, Withdrawn, Last updated: 12/12/2013
Clopidogrel ratiopharm Peripheral Vascular … Withdrawn clopidogrel Overview The marketing authorisation … marketing authorisation for Clopidogrel ratiopharm has been withdrawn … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Sandoz
clopidogrel, Peripheral Vascular Diseases, Stroke, Myocardial Infarction
Date of authorisation: 21/09/2009,, Revision: 2, Withdrawn, Last updated: 26/10/2011
Clopidogrel Sandoz Peripheral Vascular … Withdrawn clopidogrel Overview The marketing authorisation … marketing authorisation for Clopidogrel Sandoz has been withdrawn … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel Hexal
clopidogrel, Peripheral Vascular Diseases, Acute Coronary Syndrome, Myocardial Infarction, Stroke
Date of authorisation: 28/07/2009,, Revision: 2, Withdrawn, Last updated: 26/07/2012
Clopidogrel Hexal Peripheral Vascular … Withdrawn clopidogrel Overview The marketing authorisation … marketing authorisation for Clopidogrel Hexal has been withdrawn … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel ratiopharm GmbH
clopidogrel, Peripheral Vascular Diseases, Acute Coronary Syndrome, Myocardial Infarction, Stroke
Date of authorisation: 28/07/2009,, Revision: 12, Withdrawn, Last updated: 25/01/2021
Clopidogrel ratiopharm GmbH Peripheral … Withdrawn clopidogrel Overview The marketing authorisation … marketing authorisation for Clopidogrel Ratiopharm GmbH has been … -
List item
Human medicine European public assessment report (EPAR): Clopidogrel 1A Pharma
clopidogrel, Peripheral Vascular Diseases
Date of authorisation: 28/07/2009,, Revision: 1, Withdrawn, Last updated: 28/02/2011
Clopidogrel 1A Pharma Peripheral Vascular … Withdrawn clopidogrel Overview The marketing authorisation … marketing authorisation for Clopidogrel 1A Pharma has been withdrawn …